Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + pyrotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Fulvestrant + pyrotinib is a combination therapy consisting of fulvestrant, a selective estrogen receptor degrader (SERD), and pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Fulvestrant binds to and accelerates the degradation of the estrogen receptor, thereby inhibiting estrogen signaling in hormone receptor-positive breast cancer cells. Pyrotinib targets multiple members of the ErbB family (including HER1/EGFR, HER2, and HER4), irreversibly inhibiting their kinase activity to block downstream signaling pathways involved in tumor cell proliferation and survival. This combination has been investigated primarily for hormone receptor-positive/HER2-positive metastatic breast cancer patients who have progressed after trastuzumab-based therapies. Clinical studies have shown promising antitumor activity with a favorable safety profile, including robust progression-free survival even in patients with brain metastases[1][2][4].
- Brand names
- AiruiniFaslodex
- Other names
- pyrotinibfulvestrant
02
Targets
EGFR (Epidermal growth factor receptor)ESR1 (ERα)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ESR2 (ERβ)
Beyond the preview
Go deeper on fulvestrant + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + pyrotinib.